Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0

作者：Anna C. Pavlick, Charlotte E. Ariyan, Elizabeth I. Buchbinder, Diwakar Davar, Geoffrey T. Gibney, Omid Hamid, Tina J. Hieken, Benjamin Izar, Douglas B. Johnson, Rajan P. Kulkarni, Jason J. Luke, Tara C. Mitchell, Meghan J. Mooradian, Krista M. Rubin, April K.S. Salama, Keisuke Shirai, Janis M. Taube, Hussein A. Tawbi, Julia Tolley, Caressa Valdueza, Sarah A. Weiss, Michael K. Wong, Ryan J. Sullivan · 发表于：Journal for ImmunoTherapy of Cancer · 年份：2023 · DOI：10.1136/jitc-2023-006947 · 被引用次数：61 · 研究领域：Immunotherapy and Immune Responses、Ocular Oncology and Treatments、Cancer Immunotherapy and Biomarkers

Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ago, immunotherapy has completely transformed the treatment landscape of this chemotherapy-resistant disease. Combination regimens including ICIs directed against programmed cell death protein 1 (PD-1) with anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) agents or, more recently, anti-lymphocyte-activation gene 3 (LAG-3) agents, have gained regulatory approvals for the treatment of metastatic cutaneous melanoma, with long-term follow-up data suggesting the possibility of cure for some patients with advanced disease. In the resectable setting, adjuvant ICIs prolong recurrence-free survival and several are FDA-approved. Although not yet approved, neoadjuvant ICIs have also shown to improve event-free survival and remains an ongoing area of investigation. Other immunotherapy strategies, such as oncolytic virotherapy for injectable cutaneous melanoma, bispecific T-cell engager therapy for HLA-A*02:01 genotype-positive uveal melanoma, and lifileucel, an autologous tumor-infiltrating lymphocyte therapy, for unresectable or metastatic melanoma are also available to patients. Despite the remarkable efficacy of these regimens for many patients with cutaneous melanoma, traditional immunotherapy biomarkers (ie, programmed death-ligand 1 expression, tumor mutational burden, T-cell infiltrate and/or microsatellite stability) have failed to reliably predict response. F...